Pfizer’s Wyeth Purchase Adds Formidable Biologics Capabilities

January 27, 2009
Pfizer’s $68 billion acquisition of Wyeth will accomplish its goal of entering the biotech market by not only gaining access to Enbrel, a tumor necrosis factor inhibitor antibody, but by adding a “world-class” manufacturing operation that could be used to produce biosimilars. The new company would retain the Pfizer brand and diversify Pfizer’s dependence on small-molecule drugs from 90 percent to an estimated 70 percent by 2012, Pfizer CEO Jeff Kindler said.
Drug Industry Daily